Literature DB >> 21624093

The Wnt/Frizzled pathway as a therapeutic target for cardiac hypertrophy: where do we stand?

P ter Horst1, J F M Smits, W M Blankesteijn.   

Abstract

Cardiac hypertrophy is an enlargement of the heart muscle in response to wall stress. This hypertrophic response often leads to heart failure. In recent years, several studies have shown the involvement of Wnt signalling in hypertrophic growth. In this review, the role of Wnt signalling and the possibilities for therapeutic interventions are discussed. In healthy adult heart tissue, Wnt signalling is very low. However, under pathological condition such as hypertension, Wnt signalling is activated. In recent years, it has become clear that both β-catenin-dependent signalling and β-catenin-independent signalling are involved in hypertrophic growth. Several studies, both in vitro and in vivo, have shown that genetic interventions in Wnt signalling at different levels resulted in an attenuated or diminished hypertrophic response. Therefore, inhibition of Wnt signalling could provide a new therapeutic strategy for cardiac hypertrophy, but further research on the Wnts and Frizzleds involved in the different forms of cardiac hypertrophy will be needed to achieve this goal.
© 2011 The Authors. Acta Physiologica © 2011 Scandinavian Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21624093     DOI: 10.1111/j.1748-1716.2011.02309.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  21 in total

Review 1.  Mitotic and mitogenic Wnt signalling.

Authors:  Christof Niehrs; Sergio P Acebron
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

Review 2.  Wnt/β-catenin in ischemic myocardium: interactions and signaling pathways as a therapeutic target.

Authors:  Habib Haybar; Elahe Khodadi; Saeid Shahrabi
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

Review 3.  Wnt signaling, a novel pathway regulating blood pressure? State of the art review.

Authors:  Maen D Abou Ziki; Arya Mani
Journal:  Atherosclerosis       Date:  2017-05-04       Impact factor: 5.162

Review 4.  At the heart of inter- and intracellular signaling: the intercalated disc.

Authors:  Heather R Manring; Lisa E Dorn; Aidan Ex-Willey; Federica Accornero; Maegen A Ackermann
Journal:  Biophys Rev       Date:  2018-06-06

Review 5.  Cell-cell interaction in the heart via Wnt/β-catenin pathway after cardiac injury.

Authors:  Arjun Deb
Journal:  Cardiovasc Res       Date:  2014-03-03       Impact factor: 10.787

6.  Angiotensin II increases secreted frizzled-related protein 5 (sFRP5) expression through AT1 receptor/Rho/ROCK1/JNK signaling in cardiomyocytes.

Authors:  Xin Jin; Bingyan Guo; Jie Yan; Rong Yang; Liang Chang; Yaling Wang; Chenglong Miao; Suyun Liu; Hui Zhang; Yongjun Li
Journal:  Mol Cell Biochem       Date:  2015-07-01       Impact factor: 3.396

Review 7.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

8.  SOX2-mediated inhibition of miR-223 contributes to STIM1 activation in phenylephrine-induced hypertrophic cardiomyocytes.

Authors:  Zhi-Hong Zhao; Jun Luo; Hai-Xia Li; Sai-Hua Wang; Xin-Ming Li
Journal:  Mol Cell Biochem       Date:  2017-11-07       Impact factor: 3.396

9.  Secreted Frizzled-related Protein 5 Diminishes Cardiac Inflammation and Protects the Heart from Ischemia/Reperfusion Injury.

Authors:  Kazuto Nakamura; Soichi Sano; José J Fuster; Ryosuke Kikuchi; Ippei Shimizu; Kousei Ohshima; Yasufumi Katanasaka; Noriyuki Ouchi; Kenneth Walsh
Journal:  J Biol Chem       Date:  2015-12-02       Impact factor: 5.157

Review 10.  WNT Signaling in Cardiac and Vascular Disease.

Authors:  Sébastien Foulquier; Evangelos P Daskalopoulos; Gentian Lluri; Kevin C M Hermans; Arjun Deb; W Matthijs Blankesteijn
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.